Laboratory Diagnosis of Biotinidase Deficiency, 2017 Update: a Technical Standard and Guideline of the American College of Medical Genetics and Genomics
Total Page：16
File Type：pdf, Size：1020Kb
© American College of Medical Genetics and Genomics ACMG STANDARDS AND GUIDELINES Laboratory diagnosis of biotinidase deficiency, 2017 update: a technical standard and guideline of the American College of Medical Genetics and Genomics Erin T. Strovel, PhD1, Tina M. Cowan, PhD2, Anna I. Scott, PhD2, Barry Wolf, MD, PhD3 and on behalf of the ACMG Biochemical Genetics Subcommittee of the Laboratory Quality Assurance Committee Disclaimer: These ACMG Standards and Guidelines are intended as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these Standards and Guidelines is voluntary and does not necessarily assure a successful medical outcome. These Standards and Guidelines should not be considered inclusive of all proper procedures and tests or exclusive of others that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, clinical laboratory geneticists should apply their professional judgment to the specific circumstances presented by the patient or specimen. Clinical laboratory scientists and geneticists are encouraged to document in the patient’srecord the rationale for the use of a particular procedure or test, whether or not it is in conformance with these Standards and Guidelines. They also are advised to take notice of the date any particular guideline was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures. Biotinidase deficiency is an autosomal recessively inherited disorder follow-up molecular testing is warranted, and to characterize of biotin recycling that is associated with neurologic and cutaneous variables that can influence test performance and interpretation of consequences if untreated. Fortunately, the clinical features of results. the disorder can be ameliorated or prevented by administering pharmacological doses of the vitamin biotin. Newborn screening Genet Med advance online publication 5 July 2017 and confirmatory diagnosis of biotinidase deficiency encompasses both enzymatic and molecular testing approaches. These guidelines Key Words: biotinidase deficiency; clinical genetic testing; were developed to define and standardize laboratory procedures for multiple carboxylase deficiency; newborn screening; technical enzymatic biotinidase testing, to delineate situations for which standards and guidelines INTRODUCTION normal serum activity, while patients with the partial Biotinidase deficiency, also known as late-onset multiple biotinidase deficiency variant have 10–30% of mean normal carboxylase deficiency, is an autosomal recessively inherited serum activity and are largely asymptomatic. Confirmation of disorder of biotin recycling associated with secondary altera- biotinidase deficiency by DNA analysis, by either allele- tions in amino acid, carbohydrate, and fatty acid targeted methods or full-gene sequencing, may be useful. metabolism.1,2 The disorder is caused by absent or markedly Biotinidase testing may be part of a larger workup in a child deficient activity of biotinidase, a cytosolic enzyme that who exhibits clinical features suggestive of the disease, but liberates free biotin from biocytin during the normal more frequently is performed on asymptomatic infants proteolytic turnover of holocarboxylases and other biotiny- following abnormal newborn screening results. Many of the lated proteins.3 Biotinidase may also play a role in the clinical issues and frequently asked questions about biotinidase biotinylation of specific proteins, such as histones.4 The deficiency have been addressed in review articles.6,7 Because all diagnosis of biotinidase deficiency is based on demonstrating newborn screening programs in the United States and many deficient enzyme activity in serum or plasma.5 Patients with other countries worldwide include biotinidase deficiency in profound biotinidase deficiency have less than 10% of mean their panel of screened conditions, there is an increased need 1Division of Human Genetics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA; 2Department of Pathology, Stanford University Medical Center, Stanford, California, USA; 3Department of Research Administration, Henry Ford Hospital, and Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan, USA. Correspondence: Erin T. Strovel ([email protected]) The Board of Directors of the American College of Medical Genetics and Genomics approved this guideline on 21 March 2017. Submitted 3 May 2017; accepted 3 May 2017; advance online publication 5 July 2017. doi:10.1038/gim.2017.84 GENETICS in MEDICINE | Volume 00 | Number | Month 1 ACMG STANDARDS AND GUIDELINES STROVEL et al | Laboratory diagnosis of biotinidase deficiency to define and standardize laboratory approaches for enzymatic impairments in the metabolic pathways of amino acids, biotinidase testing, to delineate situations for which follow-up carbohydrates, and lipids (see Figure 1). molecular testing is warranted, and to characterize variables Biotinidase is a monomeric enzyme encoded by a single gene that can influence test performance and interpretation of (BTD) located on chromosome 3p25, and comprises 543 amino results. These guidelines describe best laboratory practices for acid residues, including 41 amino acids of a potential signal biotinidase deficiency testing including preanalytical consid- peptide.10,11 The gene spans at least 23 kilobases of genomic erations, test selection and performance, results interpretation, DNA and consists of four exons and three introns, reflecting a and appropriate follow-up testing. simple structural organization that facilitates gene sequencing to genotype patients.12 Two putative translation initiation codons exist, one in exon 1 and the other in exon 2, with the BACKGROUND second containing the N-terminal methionine of the mature Biochemical and molecular characteristics of biotinidase enzyme.12 The sequences upstream of exons 1 and 2 contain – Biotinidase (E.C. 3.5.1.12) is a 70 80 kDa glycoprotein that is promoter elements consistent with the ubiquitous expression of ubiquitously expressed and detectable in multiple tissues biotinidase as a housekeeping gene. The presence of an intron 8 including serum, leukocytes, fibroblasts, and liver. The between the two possible initiation codons could allow for enzyme recycles biotin, a water-soluble cofactor necessary alternative splicing, raising the possibility of tissue-specific for the function of four carboxylases: propionyl-CoA expression of different BTD transcripts. In support of this idea, carboxylase (E.C. 6.4.1.3), 3-methylcrotonyl-CoA carboxylase a consensus sequence for the liver-specific transcription factor (E.C. 6.4.1.4), pyruvate carboxylase (E.C. 6.4.1.1), and acetyl- HNF-5 is present at nucleotide position − 352, although the CoA carboxylase (E.C. 6.4.1.2).9 An inherited disorder of physiologic significance of this is unknown. biotin recycling or utilization, from a deficiency of biotinidase Three publicly available databases of biotinidase variants (MIM 253260) or holocarboxylase synthetase (E.C. 6.3.4.10; are accessible online: the Leiden Open Variation Database MIM 253270), leads to secondary disruptions in the activities (https://grenada.lumc.nl/LOVD2/shared1/home.php?select_ of the aforementioned carboxylases that, in turn, cause db = BTD), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), Dietary free biotin Biotin transport Lysine O– O ATP C C O N NH Biotinidase Holocarboxylase OH PPi synthetase E.C. 3.5.1.12 S C O E.C. 6.3.4.10 MIM 253260 Free biotin MIM 253270 Biotinyl-AMP Biocytin THE BIOTIN O C HN NH CYCLE H H N N NH H S C C O O Apocarboxylases Proteolysis MCC, PCC, PC, ACC O– O C C O N NH AMP Biotinylated proteins H N S C O Holocarboxylases Lipid metabolism Amino acid catabolism Gluconeogenesis 3-methylcrotonyl-CoA Propionyl-CoA Pyruvate Acetyl-CoA carboxylase carboxylase carboxylase carboxylase E.C. 6.4.1.3 E.C. 6.4.1.4 E.C. 6.4.1.1 E.C. 6.4.1.2 Figure 1 The biotin cycle. Free biotin, whose primary source is the diet, is actively transported across the intestinal membrane and blood–brain barrier. This free biotin pool provides biotin to the various apocarboxylases (pyruvate carboxylase, acetyl-CoA carboxylase, propionyl-CoA carboxylase, and beta-methylcrotonyl-CoA carboxylase). Holocarboxylase synthetase assembles active holocarboxylases by covalently binding biotin to their active sites. The carboxylases are important for gluconeogenesis, fatty acid synthesis, and the catabolism of several branch-chain amino acids. Eventually, the holocarboxylases are degraded proteolytically to biocytin or small biotinyl-peptides. These compounds are further cleaved by biotinidase to produce lysine and free biotin, which can enter the free biotin pool, thereby recycling the vitamin. ACC, acetyl-CoA carboxylase; AMP, adenosine monophosphate; ATP, adenosine triphosphate; MCC, 3-methylcrotonyl carboxylase; PC, pyruvate carboxylase; PCC, propionyl-CoA carboxylase; PPi, inorganic pyrophosphate. 2 Volume 00 | Number | Month | GENETICS in MEDICINE Laboratory diagnosis of biotinidase deficiency | STROVEL et al ACMG STANDARDS AND GUIDELINES and “Biotinidase Deficiency and BTD,” hosted by ARUP occur.29 More than 70% of clinically